FOLLOW THE MONEY
As government has been "downsized" in recent years, corporations
have found opportunities to fund scientific research and
education that the government used to fund. Will this give
corporations the chance to influence scientific and medical
opinions? Put another way, are scientific and medical experts
able to take corporate money without subtly altering their
scientific and medical views?
A recent article in the NEW ENGLAND JOURNAL OF MEDICINE1 (NEJM)
--the first research of its kind --shows pretty clearly that
scientific and medical experts who take corporate money hold
opinions that differ significantly from experts who don't take
corporate money.[1]
Researchers in Toronto, Canada examined a medical controversy to
see which scientists held what sorts of views. The controversy
they studied was the use of calcium-channel blockers, which are
used to treat high blood pressure and heart disease. In 1995 the
National Heart, Lung and Blood Institute warned doctors that one
such channel-blocker increased the risk of heart attack
deaths.[2] Other channel-blockers fell under suspicion of being
dangerous.
The Toronto researchers examined 70 articles on channel-blockers,
classified the authors into three categories (supporters,
neutral, and critical), then mailed surveys to the authors,
asking about their financial ties to drug corporations. The 70
articles had a total of 86 authors, and 71 of those returned the
surveys. The surveys were intended to answer 3 questions:
- Whether supporters of calcium-channel blockers were more
likely than other authors to have financial ties to manufacturers
of calcium-channel blockers. The answer was yes. Ninety-six
percent of the supportive authors had financial relationships
with manufacturers, as compared with 60 percent of the neutral
authors, and 37 percent of the critical authors.
- Were critics of calcium channel-blockers more likely than
other authors to have financial ties to manufacturers of
competing products (beta-blockers, angiotensin-converting-enzyme
inhibitors, diuretics, and nitrates). The answer was no. In
fact, supportive and neutral authors were more likely than
critical authors to have financial ties to manufacturers of
competing products (88% and 53% respectively, vs. 37%).
- Were supporters of calcium-channel blockers more likely than
other authors to have financial ties with ANY pharmaceutical
manufacturers? The answer was yes. One hundred percent of the
supportive authors, compared with 67% of the neutral authors, and
43% of the critical authors, had financial ties to at least one
pharmaceutical manufacturer.
Financial ties are defined as any of these five: funds for travel
expenses; honorariums for speeches; support for educational
programs; research grants; and employment or consulting
compensation.
The researchers noted that their study relied on self-reported
data and therefore probably underestimated the actual ties
between scientists and corporate funders.
The authors noted that in only 2 of the 70 articles did authors
divulge their connections to corporations. They concluded, "The
medical profession has failed to develop and enforce strict
guidelines for disclosing conflicts of interest." And, "Full
disclosure of relationships between physicians and pharmaceutical
manufacturers is necessary to affirm the integrity of the medical
profession and maintain public confidence."
Unfortunately, even the columns of the most prestigious medical
journal in the U.S. --thE NEW ENGLAND JOURNAL OF MEDICINE (NEJM)
--have been infiltrated by corporate shills posing as objective
medical experts.
Last November 20th, the NEJM printed a scathing review of Sandra
Steingraber's book, LIVING DOWNSTREAM: AN ECOLOGIST LOOKS AT
CANCER --a book that, in our opinion, outshines Rachel Carson's
SILENT SPRING. (See REHW #565). The review was signed "Jerry H.
Berke, M.D., M.P.H., 49 Windsor Ave., Acton, MA 01720" --just the
way any unaffiliated medical practitioner would sign such a
review.[3]
Berke's review began with an attack on all environmentalists: "An
older colleague of mine once suggested that the work product of
an environmentalist is controversy. Fear and the threat of
unseen, unchosen hazards enhance fund-raising for environmental
political organizations and fund environmental research, he
suggested." Berke's review went on to say that Steingraber's
book is "biased" and "obsessed with environmental pollution."
Berke ends, "The objective of LIVING DOWNSTREAM appears
ultimately to be controversy."
This was the first negative review Steingraber's book had
received. The book is now in its second printing and has been
widely praised. Steingraber herself was recently named an
"outstanding women of the year" by MS. magazine.
In early December, Bill Ravanesi, a Boston-based film producer,
and Paul Brodeur, the well-known author of books on asbestos and
electromagnetic radiation, revealed that Jerry H. Berke is
director of toxicology for W.R. Grace, one of the world's largest
chemical manufacturers and a notorious polluter. Grace is
best-known as the company that polluted the drinking water of the
town of Woburn, Massachusetts, and later paid $8 million to a
group of children (or their surviving parents) who contracted
leukemia. During the Woburn investigation, Grace was caught in
two felony lies to U.S. Environmental Protection Agency (EPA),
for which they paid a slap-on-the-wrist $10,000 fine.[4]
The Woburn story has been told in the best-selling book A CIVIL
ACTION and will soon be re-told in a movie starring John Travolta
as a hard-working attorney playing David against the Grace
Goliath.
For its part, the NEW ENGLAND JOURNAL OF MEDICINE seems flustered
and unable to get its story straight. In an interview, Sandra
Steingraber said when she first phoned the office of NEJM's book
review editor, Robert S. Schwartz, she spoke to Schwartz's
assistant, Lisa Lum, who denied that Berke was currently employed
by Grace. Lum told Steingraber that Berke was an independent
consultant.
When Steingraber phoned back and spoke to Dr. Schwartz himself,
Schwartz insisted that he did not know that Berke worked for
Grace. Schwartz told Steingraber that reviewers must fill out
statements saying they have no conflict of interest, but NEJM
does no "background checks" on reviewers.
Schwartz told Steingraber that reviewers are selected from a
database of names of people who have expressed an interest in
writing book reviews for NEJM. Lisa Lum told me (1/14/98) that
the database DOES contain the affiliations of potential
reviewers. "Oh, yes," she said, "affiliations are in there."
How then did they miss Berke's affiliation? Ms. Lum would not
say.
According to Steingraber, recently NEJM has changed its story
once again, saying they knew Berke was affiliated with W.R.
Grace, but they thought W.R. Grace was a hospital.
Jerry Berke told Michele Landsberg, a columnist for the TORONTO
STAR, that (1) the conflict-of-interest form he signed for NEJM
clearly identified his Grace connection; (2) all his
correspondence from Schwartz was addressed to him at W.R.
Grace.[5] Furthermore, Berke was identified as a Grace employee
in another book review he published in NEJM in 1995.[6]
Nevertheless, Schwartz insists he knew nothing of Berke's
connection to Grace and wouldn't have asked him to review
Steingraber's book if he HAD known.
Berke says Grace officials decided at the last minute to make him
remove his affiliation from the NEJM review.[7] Grace evidently
wanted to avoid fueling the anti-Grace flames that will probably
erupt when the Travolta movie is released later this year.
However, having admitted that his superiors at Grace made him
remove Grace's name to avoid obvious controversy, Berke still
insists he had no conflict of interest. Berke told columnist
Michele Landsberg he is "shocked" that his statement of a
"personal vision" should be construed as a conflict of
interest.[5]
The editor-in-chief of NEJM, Jerome P. Kassirer, told the
Associated Press, "It's laughable that Berke would think that he
could write an objective review of the book given that he was an
employee of W.R. Grace."[7] Unfortunately, Kassirer himself
doesn't always recognize a conflict-of-interest when he sees one.
In late 1997, Kassirer turned over the editorial columns of NEJM
to Stephen Safe, a researcher who during 1997 was receiving
$150,000 (20% of Safe's research budget) from the Chemical
Manufacturers Association (CMA).[8] Safe's editorial --like
Jerry Berke's review --began with an irrational attack against
environmentalism: "Chemophobia, the unreasonable fear of
chemicals, is a common public reaction to scientific or media
reports suggesting that exposure to various environmental
contaminants may pose a threat to health." Surely this is an odd
message from a scientist. He is saying, if you fear chemicals
because scientific reports indicate that they might harm your
health, you are suffering from an irrational phobia. Perhaps Dr.
Safe did not write the editorial in his capacity as a scientist.
Perhaps he wrote it as an acolyte of the CMA. (See REHW #574.)
In any case Safe himself told BOSTON GLOBE reporter Larry Tye, "I
felt a little twinge" about the potential for a conflict of
interest when writing the editorial, "but it was not much of a
twinge," he said. However, "I can see why people would bring it
up," he said. Safe defended himself saying, "There's hardly any
life scientist in the country who hasn't had funding from the
industry" --the old "Everybody's doing it" defense.
Unfortunately, just about everybody IS doing it. In modern
times, it pays to be alert when you are receiving opinions from
"unbiased" scientific and medical investigators. As George
Annas, professor of health law at the Boston University School of
Public Health points out, "Almost all experts in the field at
some point have taken grant money or an honorarium from someone."
In other words, if you want to understand "objectivity" in the
science and medicine of environment-and-health these days, the
same advice applies as it does in politics: follow the money.
Increased corporate funding of science and medicine has the
potential to corrupt almost anyone.
--Peter Montague
(National Writers Union, UAW Local 1981/AFL-CIO) |
| [1] Henry Thomas Stelfox and others, "Conflict of Interest in the
Debate over Calcium-Channel Antagonists," NEW ENGLAND JOURNAL OF
MEDICINE Vol. 338, No. 2 (January 8, 1998), pgs. 101-106.
[2] Richard A. Knox, "Study finds conflict in medical reports,"
BOSTON GLOBE January 8, 1998, A12.
[3] Jerry H. Berke, "Book Review: Living Downstream: An Ecologist
Looks at Cancer and the Environment," NEW ENGLAND JOURNAL OF
MEDICINE Vol. 337, No. 21 (November 20, 1997), pg. 1562.
[4] Peter B. Lord, "How Important is One Negative Book Review?"
PROVIDENCE [Rhode Island] JOURNAL-BULLETIN December 24, 1997, pg.
A-1.
[5] Michele Landsberg, "Famed journal's objectivity gets a black
eye," TORONTO STAR December 21, 1997, pg. A2.
[6] Jerry H. Berke, "[Book Review] Textbook of Clinical
Occupational and Environmental Medicine," NEW ENGLAND JOURNAL OF
MEDICINE Vol. 332, No. 5 (February 2, 1995), pgs. 340-341. This
review is signed, "Jerry H. Berke, M.D., M.P.H., Lexington, MA
02173 W.R. Grace & Co."
[7] Associated Press, "Medical Journal Apologizes for Ethics
Blunder," WASHINGTON POST December 28, 1997, pg. A3..
[8] Larry Tye, "Journal fuels conflict-of-interest debate,"
BOSTON GLOBE January 6, 1998, pgs. B1, B8.
Descriptor terms: new england journal of medicine; conflict of
interest; science; jerry berke; stephen safe; chemical
manufacturers association; cma; corporations; sandra steingraber;
living downstream; bill ravanesi; paul brodeur; woburn, ma; a
civil action;
|